Fig. 8
Evidence-based pricing simulation outcomes. A. VS. BSC; B. VS. TAS-102. BSC, Best Supportive Care; REDo, regorafenib dose optimization; TAS-102, trifluridine/tipiracil; TAS-BEV, TAS-102 with bevacizumab
Fig. 8 | Health Economics Review